ACI's 2nd Annual Summit on GLP-1 Law & Policy

Wade Ackerman will participate in the panel, “Taking Shape: The Legislative and Regulatory Landscape for GLP1s,” at ACI's 2nd Annual Summit on GLP-1 Law & Policy. Join industry leaders in-person in New York City for this timely event that will cover everything from advertising to mass torts to peptides. As the competitive landscape grows more complex, and litigation gets underway, don’t miss the chance to benchmark your approach, manage risk, and engage in critical discussions with peers and policymakers at the forefront of the GLP-1 boom.

The GLP-1 boom has led to rapid re-evaluation by the federal and state governments. Market pressures, industry particularities, and the unique nature of GLP1s are impacting the legislative tilt, but the dust has yet to settle. Identifying the contours of regulation are fundamental to ensuring long-term success and security.

Topics of discussion will include:

• Analyzing pending state and federal legislation regarding GLP-1 marketing, manufacturing, and more
• Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025/2026 (H.R. 6509/S. 3794)
• GAP Supply Act (H.R. 7528)
• Drug Shortage Compounding Patient Access Act of 2025 (H.R.5316)
• Most-Favored-Nation Prescription Drug Pricing Executive Order
• Responding to regulatory enforcement efforts from FDA
• Detangling competing pressures and their sway on governmental regulators
• Breaking down the potential consequences of pending legislation before it passes
• Assessing the implications of shifting Medicare timelines, state AG activity, and the FDA posture following their February 6 letter
• Surveying IRA/CMS Medicare negotiation mechanics and contracting implications
• Preparing for pending and potential legislation before the ball drops

Pre-registration is required. Learn more and register here.